The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed to its highest level of 2026, and the timing isn't an accident. Investors are positioning ahead of a June 29 DEA administrative hearing that will examine whether marijuana products, including adult-use cannabis, should move to Schedule III. As of May 31, MSOS posted a 103.7% one-year NAV return, well ahead of the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8%, with the fund managing $1.13 billion in assets as of June 5.
What's driving the rally isn't just sentiment. It's structural. Multi-state operators have spent years absorbing the costs of federal prohibition, from punitive tax treatment under Section 280E to limited access to institutional capital and traditional banking. Any credible movement toward rescheduling changes the math on all of it - deductible payroll, rent, and interest expenses alone can reshape a company's balance sheet. Meanwhile, at the store level, operators are still managing the basics: seed-to-sale tracking, compliant packaging, lab-tested batches, and POS systems that reconcile against state reporting requirements like METRC. A dispensary management system california operators rely on for daily compliance logs looks nothing like the capital markets conversation happening around MSOS, but the two are connected - regulatory clarity at the federal level eventually filters down to how retailers manage inventory, taxes, and wholesale pricing on the ground. dispensary management system california
Trulieve's Listing Signals a Shift, But Not a Finish Line
Trulieve Cannabis, MSOS' largest holding at roughly 30% of assets, began trading on the NYSE under TRLV this week - a listing CEO Kim Rivers described as a milestone tied directly to the administration's move to reclassify medical marijuana into Schedule III. The company split its medical and adult-use operations to qualify for a senior exchange listing, a structural workaround that other multi-state operators are watching closely. Cresco Labs' new $50 million revolving credit facility from Needham Bank, and Tilray's positioning around its at-the-market program, both point to the same pattern: operators lining up capital and legal structures now, betting that uplisting opportunities widen once rescheduling clears its next procedural hurdle.
Here's the catch, though. A listing on a senior exchange doesn't erase the underlying business risk. Trulieve trades at a 27% upside to its price target by one estimate, respectable but modest next to smaller holdings like Verano (195% upside) or Jushi Holdings (183%), according to Koyfin data cited by analysts. The market is pricing in real uncertainty about which companies convert regulatory tailwinds into durable earnings, and which simply get a valuation bump on hearing-week optimism.
What Operators and Investors Should Actually Watch
The June 29 hearing is procedural, not a guaranteed outcome. It's expected to run through no later than July 15, and rescheduling to Schedule III doesn't mean legalization - it means a different tax and banking framework, not federal permission for interstate commerce or relaxed advertising rules. For dispensary operators, that distinction matters. Compliance obligations around age verification, product testing, and state-specific packaging rules don't change with a DEA schedule shift. Retail-level risk - inventory shrinkage, cash-heavy operations, local zoning fights - stays exactly where it was.
What does change is access to capital and, potentially, the tax bill. That's why Roth Capital called the rescheduling order "extremely favorable," and why AdvisorShares points to improved balance-sheet strength across the sector. Retail sentiment on platforms like Stocktwits reflects the enthusiasm - bullish readings on MSOS, Trulieve, and Green Thumb Industries - but enthusiasm isn't a substitute for scrutiny. Operators eyeing uplisting, and investors chasing the sector's next winner, are both making the same bet: that this hearing marks a real inflection point, not another false start in an industry that has seen plenty of them.
